Seeking Alpha • Apr 15

Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026

Summary Biohaven Ltd. is downgraded from Strong Buy to Hold following the FDA's Complete Response Letter for troriluzole in Spinocerebellar Ataxia. BHVN pivots focus to three late-stage programs: MODE/TRAP degraders [BHV-1400, BHV-1300], Kv7 activator Opakalim, and myostatin-activin inhibitor taldefgrobep alfa for obesity. Taldefgrobep alfa targets obesity with a novel MOA aiming for fat loss, muscle gain, and improved safety versus GLP-1s; phase 2 POC data is expected in 2H 2026. Cash runway remains a concern after significant burn in 2025; additional capital raises are likely as pivotal data for key programs approach. Read the full article on Seeking Alpha

Analysis Article • May 02

An Intrinsic Calculation For Biohaven Ltd. (NYSE:BHVN) Suggests It's 47% Undervalued

Key Insights Biohaven's estimated fair value is US$42.26 based on 2 Stage Free Cash Flow to Equity Current share price...

Seeking Alpha • Feb 28

Biohaven's Exciting Year Of Catalysts

Summary Following Pfizer's acquisition, Biohaven's valuation surged from $300M at $7/share to over $4B at $42/share under Vlad Coric's leadership. Despite the significant valuation increase, substantial upside remains due to Biohaven's promising later-stage clinical assets with key catalysts expected in 2025. The investment thesis hinges on the potential success of these clinical assets, which could drive further valuation growth. The current valuation rise is justified by the strategic leadership and promising pipeline, suggesting continued growth potential. Read the full article on Seeking Alpha

Seeking Alpha • Feb 11

Biohaven: Highly Priced Biotech With Broad Pipeline But No Revenues

Summary Biohaven's pipeline is broad with multiple late stage molecules. Analysis based on Biohaven's 01/2025 J.P. Morgan Healthcare Conference Highlights and Presentation, Q3 2024 Earnings Release, and 10-Q. Biohaven's lead product's NDA is under review by the FDA. Article concludes with a "Hold" rating based on its hefty market cap and uncertain prospects. Read the full article on Seeking Alpha

Seeking Alpha • Nov 29

Biohaven's Revenue Path: SCA And Obesity Therapies

Summary Biohaven’s pipeline progression includes Troriluzole for spinocerebellar ataxia [SCA], which has shown a 50-70% reduction in disease progression over three years. BHV-2100, a non-opioid migraine treatment, targets unmet needs in a market affecting 40 million U.S. patients and 1 billion globally. Taldefgrobep Alfa, under investigation for SMA and obesity, demonstrated subgroup-specific motor function improvements and favorable safety in Phase 3 trials. Despite a $250 million equity raise, BHVN's cash burn of $141.9 million per quarter poses financial sustainability risks, making commercialization critical. Therefore, BHVN's positive clinical progress, high cash burn, and frequent equity raises make it a speculative buy. Read the full article on Seeking Alpha

Seeking Alpha • Oct 11

Biohaven: A Complicated Tale

Summary Biohaven's stock has surged despite past setbacks, driven by promising data from its troriluzole trials for spinocerebellar ataxia and ongoing OCD studies. The company is advancing a diverse pipeline, including myostatin inhibitor taldefgrobep alfa for SMA and obesity, and Kv7 ion channel activator BHV-7000 for epilepsy. Biohaven's strategic capital raises, and positive clinical data have rallied its stock, but future dilution risks remain if trials disappoint. An updated analysis of Biohaven follows in the paragraphs below. Read the full article on Seeking Alpha

Seeking Alpha • Sep 23

Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst

Summary Biohaven Ltd. reported positive results from a pivotal study using troriluzole for the treatment of patients with spinocerebellar ataxia; the Drug achieved 50% to 70% of slowing of disease progression over 3 years. With positive data on hand from the phase 3 study using troriluzole for patients with spinocerebellar ataxia, an NDA submission is planned for Q4 of 2024. Troriluzole is also being explored for patients with obsessive compulsive disorder in two phase 3 studies; Data from these studies are expected before the end of 2024 and the 1st half of 2025. Topline data from the phase 3 study using Taldefgrobep Alfa for SMA is expected 2nd half of 2024; the Drug is also expected to be initiated in a phase 2 study for obesity as well. Read the full article on Seeking Alpha

Seeking Alpha • Jul 26

Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment

Summary Results from phase 3 RESILIENT study, using taldefgrobep alfa for the treatment of patients with spinal muscular atrophy, expected in the 2nd half of 2024. The global spinal muscular atrophy treatment market is projected to reach $8.4 billion by 2032. Preclinical model testing showed that myostatin inhibitor taldefgrobep alfa + GLP-1 inhibitor was able to show greater reductions in body weight and fat loss, compared to that of GLP-1 alone. It is expected that the global obesity treatment market size is expected to be worth $38 billion by 2032. Read the full article on Seeking Alpha

Seeking Alpha • May 18

Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge

Summary Biohaven Ltd. is a spinout of Biohaven Pharmaceutical, focusing on developing drugs in the life sciences field. BHVN has three Phase 3 drug candidates: troriluzole for OCD, taldefgrobep alfa for SMA, and BHV-7000 for epilepsy and bipolar disorder. Also, the company has a diverse pipeline of drugs in various stages, including those targeting neurology, immunology, and oncology. Upcoming catalysts include FDA approval decisions and clinical trial results, which could significantly impact BHVN's stock performance. Despite the short cash runway, BHVN is a 'buy' due to its promising drug candidates and upcoming catalysts. Read the full article on Seeking Alpha

Analysis Article • Apr 06

We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. By way of example, Biohaven...

Analysis Article • Mar 01

Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Biohaven fair value estimate is US$49.64 With US$48.14 share...

Seeking Alpha • Feb 28

Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)

Summary Biohaven's stock rose 130% post "Sell" recommendation; overlooked assets like BHV-7000 suggest early growth stages remain. The company's pipeline, particularly their Kv7 activators and IgG degrader, show promise and have blockbuster potential in treating epilepsy and immune-mediated diseases. Financially, with a cash runway extended to 20.7 months post-offering, Biohaven shows robust short-term health. Upgrading BHVN to "Buy" due to pipeline promise and market potential, despite competition risks and high cash burn. Read the full article on Seeking Alpha

Seeking Alpha • Dec 08

Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade)

Summary Today, we circle back on a promising biopharma concern called Biohaven Ltd., whose shares have had a significant rally in recent months. The company has a diverse pipeline of therapies for neurological and neuropsychiatric diseases, with a mixture of early and late-stage candidates. A portfolio review and analysis around Biohaven follow in the paragraphs below. Read the full article on Seeking Alpha

Analysis Article • Dec 04

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, Biohaven...

Seeking Alpha • Sep 27

Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True

Summary Biohaven's stock surged nearly 30% following updates on its preclinical asset, the IgA degrader BHV-1300. The company's stock has risen more than 270% since its spinout from parent company Biohaven Pharmaceutical. Biohaven's preclinical pipeline includes assets targeting a wide range of central nervous system conditions and autoimmune diseases. As intriguing as today's data was, it does not necessarily support the buy case for Biohaven. Arguably, the data may have been released in response to promising IgG removal data released by Immunovant earlier this week. Time will tell, but I'm on the sidelines. Read the full article on Seeking Alpha

Seeking Alpha • Aug 28

Biohaven's Valuation Challenge: Weighing Potential Against Setbacks

Summary Biohaven faces FDA rejection for troriluzole; explores further discussions and potential subgroup focus. Despite FDA setback, Biohaven maintains a strong cash position, diversified pipeline, and ongoing R&D efforts. Given current uncertainties and valuation, I recommend a "Sell" stance on Biohaven's stock. Read the full article on Seeking Alpha

Analysis Article • Jul 22

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Seeking Alpha • Jun 14

Biohaven: A Promising Investment In Innovative Neurological Therapies

Summary Biohaven offers a diverse portfolio of innovative drug development assets targeting various therapeutic areas, with a focus on neurodegenerative and neuroinflammatory conditions. The company's robust financials, diverse revenue streams, and recent performance results indicate a bright future and strong investment potential. Biohaven's innovative approaches and unique mechanisms of action set it apart from competitors, positioning the company as a compelling investment opportunity in the biopharmaceutical industry. Read the full article on Seeking Alpha

Seeking Alpha • Jun 06

Biohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A Headache

Summary Biohaven Ltd is a spinout of assets from Biohaven Pharmaceutical - just before the parent company was acquired by Pfizer last year for >$11bn. Much of the management team that developed Biohaven Pharmaceuticals' Nurtec migraine therapy, plus six other pipeline assets acquired by Pfizer, appear to be working at the new company. Biohaven Ltd shares have risen in value from ~$6, to >$20 - +265% in less than one year. An investor day presentation delivered last week appears to have generated significant upside momentum. An NDA has been submitted to the FDA for approval of a spinocerebellar ataxia Type 3 drug. At a market cap valuation of nearly $1.5bn and with no other near-term approval shots in play, Biohaven shares are not cheap, but the team is experienced. I would not be surprised if the upside momentum continues. Read the full article on Seeking Alpha

Analysis Article • Apr 06

Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Seeking Alpha • Feb 21

Biohaven's spinal muscular atrophy therapy gets FDA fast track status

The U.S. Food and Drug Administration (FDA) granted fast track designation to Biohaven (NYSE:BHVN) medicine taldefgrobep alfa to treat spinal muscular atrophy (SMA). SMA is an inherited motor neuron disorder characterized by loss of nerve cells leading to muscle weakness over time. The company noted that taldefgrobep (also known as BHV2000) had previously received received orphan drug designation from the FDA to treat SMA. The drug is currently undergoing a phase 3 trial dubbed RESILIENT. Pfizer had acquired Biohaven Pharmaceuticals but a separate company Biohaven Ltd. was spunoff before the acquisition closed. BHVN +1.82% to $16.81 premarket Feb. 21

Seeking Alpha • Dec 07

Biohaven Ltd: Assessing The Spinoff

Summary Shares of neuro-pharmaceutical concern Biohaven Ltd. (BHVN) have more than doubled after being spun out as part of Pfizer’s (PFE) purchase of the legacy company’s migraine assets. The one-month move was accomplished despite a secondary that diluted shareholders by 73% and two duds from its late-stage programs since May 2022. With nearly $8 in cash and an early-stage program with blockbuster potential, the recent insider buying merited a deeper dive. A full investment analysis follows in the paragraphs below. While there's life, there's hope.”― Marcus Tullius Cicero Today we take a look at a spin out from a company that made me some money when it was purchased by Pfizer (PFE) for a healthy buyout premium. Its 'offspring' seems to have some potential attractive assets. An analysis follows below. Company Overview Biohaven Ltd. (BHVN) is a British Virgin Islands domiciled and New Haven, Connecticut based clinical-stage biopharmaceutical concern focused on the development of therapies that leverages its expertise in neuropharmacology. The company currently has four clinical programs pursuing five indications. Biohaven Ltd. was spun out of legacy Biohaven just prior to Pfizer’s October 3, 2022 acquisition of the latter. For a consideration of $11.6 billion, Pfizer received Biohaven’s calcitonin gene-related peptide (CGRP) receptor agonist franchise, including migraine therapies Nurtec ODT (rimegepant) and NDA-filed zavegepant, as well as a portfolio of preclinical assets. Post-transaction, the ‘new’ Biohaven had a reset value of $6.39 a share (based on its opening transaction) but has quickly moved higher. The stock currently trades just over $15.50 a share, translating to a market cap of just north of $1 billion. Platforms With its CGRP platform now in the hands of Pfizer, the company’s retained programs are spawned from four distinct mechanistic development platforms: glutamate; myostatin; Kv7; and antibody recruiting molecule (ARM). Glutamate is an excitatory transmitter in the brain, the modulation of which is being studied as a treatment for spinocerebellar ataxia [SCA] and obsessive-compulsive disorder (OCD). Myostatin is a natural protein that limits skeletal muscle growth, an important process in healthy muscular development. However, in patients with neuromuscular diseases, active myostatin can retard growth, resulting in underdevelopment and dysfunction. The Kv7 ion-channel modulation platform was acquired from Knopp Biosciences in April 2022 and just received approval to enter the clinic in Canada to tackle several indications, with the first one focal epilepsy. Unlike the other three neuro-focused approaches, Biohaven’s ARM platform is the output of a collaboration with Japanese firm PeptiDream (PPTDF) and was developed to produce compounds that induce antibody-mediated immune responses while circumventing antibody administration. Pipeline Troriluzole. Biohaven’s glutamate modulation platform has developed troriluzole, a tripeptide prodrug of an active metabolite (riluzole) that has been assessed or is undergoing evaluation as a remedy for general anxiety disorder, Alzheimer’s, SCA, and OCD. It can be described as a longshot for any approval for multiple reasons. After failing to separate from placebo in the treatment of general anxiety disorder in a Phase 2/3 study in 2020, troriluzole flunked a Phase 2/3 study evaluating it in the treatment of mild-to-moderate Alzheimer’s patients in early 2021. Then in May 2022, Biohaven announced that troriluzole failed to successfully treat all types of SCA (n=213; p=0.053), with only one subgroup (with the SCA3 genotype) achieving statistical significance (n=89; p=0.031). Management expects to huddle with the FDA to discuss a possible path forward targeting the SCA3 genotype. On the OCD front, Biohaven is forging ahead with troriluzole in two identical 600 moderate-to-severe OCD-patient Phase 3 trials (U.S. and global), after demonstrating improvement but not statistical significance over placebo on the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) (p=0.22 at week 12) in a Phase 2 study. Given its known safety profile to date, the company is upping its dosage 40% and combining it with current standard of care (SOC), which will be measured against placebo plus SOC. Enrollment is not expected to complete until FY23. Taldefgrobep alfa. Biohaven’s other later-stage program is taldefgrobep alfa [TA], an anti-myostatin adnectin (antigen binding moiety) acquired from Bristol-Myers Squibb (BMY) in February 2022. It is undergoing a 180-patient Phase 3 study to evaluate its effectiveness and safety in the treatment of spinal muscle atrophy [SMA], a rare (1 in 11,000), progressively debilitating motor neuron disease that hinders muscle mass development, resulting in weakness, muscle atrophy, reduced motor function, and often death. TA is being evaluated in combination with nusinersen or risdiplam or in patients who have received onasemnogene abeparvovec-xioi – all versus placebo. Initiated in July 2022, there is no timeline for data yet. The reason TA became available to Biohaven is due to its failure in the treatment of Duchenne muscular dystrophy. Biohaven paid no upfront money to Bristol but could owe up to $200 million in milestones and royalties from the high teens to the low twenties. BHV-7000. When Biohaven acquired its Kv7 platform, the lead asset was BVH-7000, a potassium channel activator that exhibited a preclinical profile suggestive of broad efficacy, high selectivity, and significantly reduced GABA-ergic activity, all suggestive of a marked improvement over current (and past) Kv7-targeting therapies. Backing up a bit, Kv7 is a family of ion channels comprising five subtypes that are preferentially expressed in tissues and organs. Kv7 protein forms a channel that modulates the flow of charged potassium ions across cell membranes, repolarizing nerve cells and resetting them for potential firing. Biohaven is initially targeting the two Kv7 subtypes (Kv7.2/7.3) found in the cortex and hippocampus. Dysfunction of these channels increases the risk of seizure. There are two Kv7 therapies that are/were on the market and another in the clinic. Potiga (ezogabine) was approved for the treatment of refractory epilepsy in 2011 but was voluntarily withdrawn in 2017 due to poor tolerability and an adverse event profile that included dizziness and somnolence, largely the result of off-target activity at the GABA brain ion channel. The other Kv7-targeted therapy is flupirtine, which is approved in Europe for acute pain but is riddled by liver toxicity issues. Xenon Pharmaceuticals’ XEN1101 is undergoing assessment for the treatment of several seizure indications in clinical trials but appears to possess a narrower therapeutic index than BHV-7000 and is menaced by off-target GABA activity. Like XEN1101, Biohaven believes BHV-7000 will target a broad range of indications – the first being focal epilepsy, a disease afflicting ~3.5 million Americans and 50 million globally, for which a Phase 1 study was initiated in 2H22 with data expected in 1H23. If successful, management expects to initiate at least one pivotal epilepsy trial in 2H23. For the Kv7 platform, the company paid Knopp a total upfront consideration of $93.8 million, consisting of cash and legacy Biohaven stock. Knopp is also eligible to receive milestones of $887 million on BHV-7000 and mid-single digit to low teens royalties. BHV-1100. In addition to Biohaven’s neurological programs, it owns BHV-1100, an antibody recruiting molecule that is being studied in combination with autologous cytokine induced memory-like natural killer cells and immune globulin to target and kill multiple myeloma [MM] cells expressing the cell surface protein CD38. A Phase 1a/1b study initiated in 4Q21 and is expected to enroll 30 newly diagnosed MM patients.

Seeking Alpha • Nov 09

Biohaven Non-GAAP EPS of -$1.25

Biohaven press release (NYSE:BHVN): Q3 Non-GAAP EPS of -$1.25. Cash as of September 30, 2022 was $50.7 million, excluding $0.8 million of restricted cash, compared to $76.1 million as of December 31, 2021.

Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Historical stock prices
Current Share Price	US$8.76
52 Week High	US$18.57
52 Week Low	US$7.48
Beta	3.31
1 Month Change	-20.22%
3 Month Change	-22.89%
1 Year Change	-45.32%
3 Year Change	-37.87%
5 Year Change	n/a
Change since IPO	20.00%

	BHVN	US Biotechs	US Market
7D	-11.2%	-1.6%	-0.3%
1Y	-45.3%	34.3%	24.0%

BHVN volatility
BHVN Average Weekly Movement	9.5%
Biotechs Industry Average Movement	10.8%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

BHVN fundamental statistics
Market cap	US$1.32b
Earnings (TTM)	-US$647.68m
Revenue (TTM)	n/a

BHVN income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$647.68m
Earnings	-US$647.68m

Earnings per share (EPS)	-4.30
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	186.8%

Data	Last Updated (UTC time)
Company Analysis	2026/05/17 13:03
End of Day Share Price	2026/05/15 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

Analyst	Institution
Brian Skorney	Baird
William Pickering	Bernstein
Dina Ramadane	BofA Global Research

Biohaven (BHVN) Stock Overview

Rewards

Risk Analysis

Biohaven Ltd. Competitors

SELLAS Life Sciences Group

Bicara Therapeutics

MapLight Therapeutics

ArriVent BioPharma

Price History & Performance

Recent News & Updates

Biohaven Narrows Quarterly Loss and Targets Key Clinical Trial Launches in 2026

Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026

Biohaven Ltd. Completes Enrollment In Phase 2 Obesity Study With Taldefgrobep Alfa

Biohaven Ltd., Annual General Meeting, Apr 28, 2026

New major risk - Financial position

Insufficient new directors

Recent updates

Biohaven Narrows Quarterly Loss and Targets Key Clinical Trial Launches in 2026

Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026

Biohaven Ltd. Completes Enrollment In Phase 2 Obesity Study With Taldefgrobep Alfa

Biohaven Ltd., Annual General Meeting, Apr 28, 2026

New major risk - Financial position

Insufficient new directors

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs

New major risk - Share price stability

Biohaven Ltd. Presents Clinical Safety and Efficacy Data for BHV-1510

Price target decreased by 7.3% to US$39.07

New major risk - Shareholder dilution

Biohaven Ltd. has completed a Follow-on Equity Offering in the amount of $175.000005 million.

New major risk - Negative shareholders equity

Price target decreased by 8.1% to US$42.13

Biohaven Ltd. Announces FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia

Pomerantz Law Firm Announces the Filing of A Class Action against Biohaven Ltd. and Certain Officers

Consensus revenue estimates decrease by 50%

Price target decreased by 7.7% to US$50.01

Pomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd

Consensus revenue estimates decrease by 22%

Biohaven Ltd. Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor

Biohaven Ltd. Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and Fgfr3 Antibody Drug Conjugates Incorporating Novel Topoix Payload with Potential to Treat A Wide Variety of Tumors

New major risk - Financial position

Consensus revenue estimates fall by 38%

Fda Extends Pdufa Date of Biohaven's Troriluzole Nda for Rare Disease Spinocerebellar Ataxia

An Intrinsic Calculation For Biohaven Ltd. (NYSE:BHVN) Suggests It's 47% Undervalued

Consensus revenue estimates decrease by 14%

Biohaven Ltd. announced that it expects to receive $400 million in funding

New minor risk - Share price stability

Biohaven Ltd. Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting

Biohaven Ltd., Annual General Meeting, May 05, 2025

Independent Director recently bought US$892k worth of stock

Biohaven Corporation Announces Acceptance and Priority Review by the United States Food and Drug Administration of the New Drug Application for Troriluzole in All-Genotype Spinocerebellar Ataxia

Biohaven's Exciting Year Of Catalysts

Biohaven Ltd. Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia

Biohaven: Highly Priced Biotech With Broad Pipeline But No Revenues

Independent Director recently bought US$1.0m worth of stock

Biohaven Ltd. Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested

Biohaven's Revenue Path: SCA And Obesity Therapies

Biohaven Ltd. Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity

New major risk - Financial position

Biohaven: A Complicated Tale

Biohaven Ltd. has completed a Follow-on Equity Offering in the amount of $250.000005 million.

Biohaven Ltd. Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine

Price target increased by 9.2% to US$62.36

Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst

Consensus EPS estimates fall by 21%

New major risk - Financial position

Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment

Independent Director recently bought US$1.0m worth of stock

Chief Scientific Officer recently bought US$1.0m worth of stock

Independent Director recently bought US$996k worth of stock

Biohaven Ltd. Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas Including Immunology, Neuroscience, Metabolic Disorders and Oncology At Annual Investor R&D Day

Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors

New minor risk - Share price stability

Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge

Consensus EPS estimates fall by 23%

Independent Director recently bought US$1.0m worth of stock

Independent Director recently bought US$999k worth of stock

Biohaven Ltd. has completed a Follow-on Equity Offering in the amount of $230.000037 million.

We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate

Now 21% overvalued after recent price rise

Biohaven Ltd., Annual General Meeting, Apr 30, 2024